Mark S. Chapman

Mark S. Chapman, PhD, currently serves as the Director of Biology at EnduRx Pharmaceuticals Inc. and as a Scientific Advisor for both Yatiri Bio Inc. and Reglagene. With extensive experience in oncology drug discovery, Mark provides strategic consulting services to a variety of clients, including startups and large pharmaceutical companies. Previously, Mark founded Crux Therapeutics, where key advancements were made in drug development with minimal funding. Mark has also contributed to research at Molecular Response, Biogen Idec, Ardea Biosciences, and Ligand Pharmaceuticals, specializing in translational oncology and molecular biology. Mark holds a PhD in Biochemistry and Molecular Biology from the University of Arizona and a Bachelor's degree in Genetics from the University of California, Berkeley, alongside training at the Salk Institute for Biological Studies.